BCL6 and diffuse large B-cell lymphoma: The data presented here indicates that in GCB-DLBCL BCL6 inhibitors could serve as crucial building blocks for novel rationally designed combinatorial therapies geared towards more effectively eradicating lymphomas with less toxicity than current chemotherapy-based regimens.